Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lantheus (LNTH)
NASDAQ:LNTH
Lantheus (LNTH) Stock Price & Analysis
1,021 Followers
LNTH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$50.20 - $100.85
Previous Close$64.41
Volume603.02K
Average Volume (3M)892.51K
Market Cap
$4.42B
Enterprise Value$4.36B
Total Cash (Recent Filing)$614.13M
Total Debt (Recent Filing)$561.28M
Price to Earnings (P/E)13.9
Beta0.77
Next Earnings
May 02, 2024EPS Estimate
$1.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.64
Shares Outstanding68,525,556
10 Day Avg. Volume704,551
30 Day Avg. Volume892,515
Standard Deviation0.17
R-Squared0.03
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)7.32
Price to Sales (P/S)4.78
Price to Cash Flow (P/CF)9.80
P/FCF Ratio9.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.62
Enterprise Value/Gross Profit7.50
Enterprise Value/Ebitda33.83
Forecast
1Y Price Target
$97.14Price Target Upside48.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Lantheus News
Bulls Say, Bears Say
Bulls Say
Innovation And Pipeline DevelopmentInvestors are interested in Lantheus' pipeline assets, including an Alzheimer’s Tau PET imaging agent, which could become future growth drivers and contribute to the company’s success.
Market Leadership And Growth PotentialPylarify maintains a market leadership position in PSMA PET agents for prostate cancer due to its first-mover advantage and established use in medical practice, suggesting a sustained growth trajectory.
Strategic Partnerships And Market ExpansionLantheus is seen as a potential 'partner of choice in radiopharmaceuticals', which may expand their presence in the radiopharma market and drive future growth.
Bears Say
Clinical Trial ResultsLNTH shares are -38% since mid-December following the headline readout of the Phase 3 SPLASH study which showed sub-par efficacy versus Pluvicto.
Regulatory ConcernsPass-through status remains an overhang on LNTH’s valuation, with the expiration affecting the payment scheme for a portion of patients.
Stock VolatilityThe stock has been volatile recently, but much of the downside could be priced in at current levels.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
LNTH FAQ
What was Lantheus’s price range in the past 12 months?
Lantheus lowest stock price was $50.20 and its highest was $100.85 in the past 12 months.
What is Lantheus’s market cap?
Currently, no data Available
When is Lantheus’s upcoming earnings report date?
Lantheus’s upcoming earnings report date is May 02, 2024 which is in 6 days.
How were Lantheus’s earnings last quarter?
Lantheus released its earnings results on Feb 22, 2024. The company reported $1.75 earnings per share for the quarter, beating the consensus estimate of $1.431 by $0.319.
Is Lantheus overvalued?
According to Wall Street analysts Lantheus’s price is currently Undervalued.
Does Lantheus pay dividends?
Lantheus does not currently pay dividends.
What is Lantheus’s EPS estimate?
Lantheus’s EPS estimate is $1.54.
How many shares outstanding does Lantheus have?
Lantheus has 68,551,410 shares outstanding.
What happened to Lantheus’s price movement after its last earnings report?
Lantheus reported an EPS of $1.75 in its last earnings report, beating expectations of $1.431. Following the earnings report the stock price went up 14.706%.
Which hedge fund is a major shareholder of Lantheus?
Among the largest hedge funds holding Lantheus’s share is Private Capital Management, LLC. It holds Lantheus’s shares valued at 35M.
---
Lantheus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$97.14 (48.99% Upside)
$97.14 (48.99% Upside)
Blogger Sentiment
Bullish
LNTH Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 5.0%
Last 30 Days ▼ 5.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.51%
12-Months-Change
Fundamentals
Return on Equity
51.73%
Trailing 12-Months
Asset Growth
24.97%
Trailing 12-Months
Company Description
Lantheus
Lantheus Holdings, Inc. engages in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, sonographers and technologists working in a variety of clinical settings. The firm operates through the following geographical segments: U.S. and International. The U.S. segment produces and markets medical imaging agents and products throughout the U.S. This segment sells its products to radio pharmacies, integrated delivery networks, hospitals, clinics and group practices. The International segment operations consist of production and distribution activities in Puerto Rico and direct distribution activities in Canada. The company was founded in 1956 and is headquartered in North Billerica, MA.
---
LNTH Company Deck
---
LNTH Earnings Call
Q4 2024
0:00 / 0:00
---
LNTH Revenue Breakdown
65.67% PYLARIFY
21.58% DEFINITY
6.74% TechneLite
4.00% Strategic Partnerships and other revenue
2.01% Other
---
LNTH Stock 12 Months Forecast
Average Price Target
$97.14
▲(48.99% Upside)
Technical Analysis
Best Analysts Covering LNTH
1 Year
1 Year Success Rate
10/18 ratings generated profit
1 Year Average Return
+0.10%
reiterated a buy rating 10 days ago
Copying Roanna Ruiz's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +0.10% per trade.
---